SEC Comment Letter for Lexaria Bioscience Corp. (LEXX) (CIK 0001348362) (LEXX) — Dec 2, 2024
Lexaria Bioscience Corp. (LEXX) (CIK 0001348362)
Date: Dec. 2, 2024 · CIK: 0001348362 · Accession: 0000000000-24-013267
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283484
Letter
December 2, 2024 Richard Christopher Chief Executive Officer Lexaria Bioscience Corp. 100 - 740 McCurdy Road Kelowna, British Columbia VIX 2P7 Re:Lexaria Bioscience Corp. Registration Statement on Form S-3 Filed November 26, 2024 File No. 333-283484 Dear Richard Christopher: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Avital Perlman, Esq.
Show Raw Text
December 2, 2024
Richard Christopher
Chief Executive Officer
Lexaria Bioscience Corp.
100 - 740 McCurdy Road
Kelowna, British Columbia VIX 2P7
Re:Lexaria Bioscience Corp.
Registration Statement on Form S-3
Filed November 26, 2024
File No. 333-283484
Dear Richard Christopher:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Avital Perlman, Esq.